Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines

Cancer Research

Volumn 64, Issue 22, 2004, Pages 8411-8419

  Ito, Fumito ^a,b   Li, Qiao ^a   Shreiner, Andrew B ^a   Okuyama, Ryuji ^a   Jure Kunkel, Maria N ^c   Teitz Tennenbaum, Seagal ^a   Chang, Alfred E ^a,d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c BRISTOL MYERS SQUIBB   (United States)

^d 3302 Cancer Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR LYSATE PULSE DENDRITIC CELL VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT CHEMOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE DEPLETION; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; SUBCUTANEOUS TISSUE TUMOR; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR MODEL; TUMOR REGRESSION; TUMOR REJECTION; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD137; CANCER VACCINES; FEMALE; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; PHENOTYPE; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES;

EID: 8544249166     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0590     Document Type: Article

References (34)

1. Mayordoma JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat Med 1995;1:1-6.
2. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl Acad Sci USA 1998;95:9482-7.
3. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000;60:1028-34.
4. Lambert LA, Gibson GR, Maloney M, et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective anti-tumor immunity. Cancer Res 2001;61:641-6.
5. Gatza E, Okada CY. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol 2002;169:5227-35.
6. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
7. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
8. Morse MA, Deng Y, Coleman D, et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-8.
9. + progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.
10. Chang AE, Redman B, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002;8:1021-32.
11. Kwon BS, Tan KB, Ni J, et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997;272:14272-6.
12. Wilcox RA, Chapoval AI, Gorski KS, et al. Expression of functional CD137 receptor by dendritic cells. J Immunol 2002;168:4262-7.
13. Takahashi C, Mittler RS, Vella AT. Differential clonal expansion of CD4 and CD8 T cells in response to 4-1BB ligation: contribution of 4-1BB during inflammatory responses. Immunol Lett 2001;76:183-91.
14. Lee HW, Park SJ, Choi BK, et al. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002;169:4882-8.
15. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;1997;3:682-5.
16. Wilcox R, Flies D, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. Clin Investig 2002;109:651-9.
17. Barth RJ, Bock SN, Mulé JJ, Rosenberg SA. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol 1990;144:1531-7.
18. 18. Tanigawa K, Takeshita N, Eickhoff GA, Shimizu K, Chang AE. Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines. J Immunother 2001;24:493-501.
19. Geiger JD, Wagner PD, Shu S, Chang AE. A novel role for autologous tumor cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg Oncol 1992;1:199-208.
20. Catipovic B, Talluri G, Oh J, et al. Analysis of the structure of empty and peptide-loaded major histocompatibility complex molecules at the cell surface. J Exp Med 1994;180:1753-61.
21. Wexler H. Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst (Bethesda) 1966;36:641-5.
22. Aruga A, Aruga E, Cameron MJ, Chang AE. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. J Leukocyte Biol 1997;61:1-10.
23. Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res 1996;56:4338-42.
24. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 1998;160:3444-52.
25. Grolleau A, Misek D, Kuick R, Hanash S, Mulé J. Inducible expression of macrophage receptor marco by dendritic cells following phagocytic uptake of dead cells uncovered by oligonucleotide arrays. J Immunol 2003;171:2879-88.
26. Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang A. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res 2003;63:2546-52.
27. Miller RE, Jones J, Le T, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 2002;169:1792-800.
28. Taraban VY, Rowley TF, O'Brien L, et al. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol 2002;32:3617-27.
29. Wilcox R, Tamada K, Strome S, Chen L. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 2002;169:4230-6.
30. Halstead ES, Mueller YM, Altman JD, Katsikis PD. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol 2002;3:536-41.
31. Cooper D, Bansal-Pakala P, Croft M. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur J Immunol 2002;32:521-9.
32. Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001;167:1313-24.
33. + T cells. Int Immunol 2002;14:1155-67.
34. May K Jr, Chen L, Zheng P, Liu Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 2002;62:3459-65.